Cango receives NYSE notice after shares trade below $1 average for 30 days

Reuters04-01
Cango receives NYSE notice after shares trade below $1 average for 30 days
  • Cango received NYSE notice dated March 10, 2026, citing non-compliance with continued listing rules tied to share-price thresholds.
  • NYSE flagged average closing price below USD 1 over 30 consecutive trading days as of March 9, 2026.
  • Six-month cure period applies to regain compliance with minimum price standard.
  • Failure to meet required closing price and 30-day average by end of cure period would trigger suspension and delisting procedures.
  • Cango notified NYSE of intent to cure deficiency while evaluating options to address price weakness.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cango Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202604010706PR_NEWS_USPR_____CN24678) on April 01, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment